Report #2881771

Received Jan 14, 2026

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: 53 yrs
State: CO
Recovered: Unknown
Vaccinated: Jan 6, 2026
Onset: Jan 6, 2026
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	2	X5FN4	SC

Symptoms (1)

Incorrect route of product administration

Symptom narrative

Shingrix was given via SC (subcutaneous) administration to a patient. This was the second dose of Shingrix for the patient and was administered yesterday on January 6, 2026; This non-serious case was reported by a nurse via call center representative and described the occurrence of intramuscular formulation administered by other route in a 53-year-old female patient who received Herpes zoster (Shingrix) (batch number X5FN4, expiry date 17-JUN-2027) for prophylaxis. Previously administered products included Shingrix (1st dose received on 18-AUG-2025). On 06-JAN-2026, the patient received the 2nd dose of Shingrix (subcutaneous). On 06-JAN-2026, an unknown time after receiving Shingrix, the patient experienced intramuscular formulation administered by other route (Verbatim: Shingrix was given via SC (subcutaneous) administration to a patient. This was the second dose of Shingrix for the patient and was administered yesterday on January 6, 2026). The outcome of the intramuscular formulation administered by other route was not applicable. Additional Information: GSK Receipt Date: 07-JAN-2026 The reporter wanted to know what they had to do and whether patient needed to be revaccinated.